Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508784 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KCNH2CACNA1ICACNA1GCHRM2 | |
| SCHEMBL15014514 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KCNH2CACNA1ICACNA1GCHRM2 | |
| SCHEMBL12561242 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KCNH2CACNA1ICACNA1GCHRM2 | |
| SCHEMBL25597177 | 0.86 | ACHE (0.33) | SMN1; SMN2 | |
| SCHEMBL12560838 | 0.84 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL13906066 | 0.84 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL12425829 | 0.83 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL12536241 | 0.81 | RORC (0.35) | SMN1; SMN2 | |
| SCHEMBL12560839 | 0.81 | DPP4 (0.36) | SMN1; SMN2 | |
| SCHEMBL12536234 | 0.81 | KCNH2 (0.36) | SMN1; SMN2KCNH2CACNA1ICACNA1GCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | SMN1; SMN2 4086/4885KCNH2 2385/4885CACNA1I 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.